AdipoLABs establishes a bridgehead to enter the Chinese market 

‘Seoul-Chengdu Medical and Health Industry Cooperation Conference’ held to strengthen understanding and cooperation in the medical and health industries of both countries

▲ Speakers and officials from the Seoul-Chengdu Pharmaceutical and Health Industry Cooperation Conference took a commemorative photo.

【Health News】 AdipoLABs Co., Ltd., which is delivering hope to cancer patients around the world by developing unique state of the art high-frequency hyperthermia cancer treatment device ‘REMISSION 1℃’, has established a bridgehead to enter the Chinese market in earnest.

The 'Seoul-Chengdu Pharmaceutical and Health Industry Cooperation Conference', hosted by IVRA (International Virus Research Council Chairman Yoo Seung-mo) and sponsored by AdipoLABs (CEO Han Sung-ho), was held on the 20th in the Bipa Room on the 3rd floor of The K Hotel in Yangjae-dong, Seoul. Wang Hongbin, Director of the Civil Affairs Bureau of Chengdu City, and Chinese high-ranking officials as well as medical company officials have all attended the event. Approximate total of 70 executives from leading domestic cancer treatment hospitals and related medical companies showed up at this time.

At the conference, hospitals and related companies in Chengdu, China including Yang Tuolai, secretary general of the Chengdu Health Service Industry Chamber of Commerce, Yang Faxiang, vice chairman of Christie's Health Industry Group, Guo Yongsheng, founder of Chengdu Jamiyunchang Science and Technology Co., Ltd., Liu Shuzhen, director of Chengdu Huimin Hospital, and Liu Songlin. Tang Jinsong, general manager of Chengdu Tsuruidi Medical Science and Technology Co., Ltd., and Tang Jinsong, general manager of Chengdu Kang Mi-shin Investment Co., Ltd., appeared as speakers and explained in detail the hospital facilities and major medical examination subjects in Chengdu City, as well as the products and patents produced within the company and its business feasibility.

In addition, domestic Korean medical companies and institutions were introduced on the day. Among them were Cha Byeong-ryeol, director of the Gimhae Biomedical Industry Promotion Agency, Ryu Jeong-man, director of Cheongju Navisol Oriental Medicine Hospital, Yang Jae-ho, director of Jongro Chihu Oriental Hospital in Seoul, Lee Jae-gwan, CEO of Natures Farm, Kim Deok-gyu, Zerone Cellvane CEO, and Yoo Seong-cheol, CEO of Red & Blue. , Kim Seon-man, director of Suwon Amirang Clinic, and Kim Soo-kyung, president of Jeju Wooridul Green International Hospital. They attended as speakers and shared domestic cancer treatment cases while emphasizing the efficacy of medicines and related health products.

In addition, Kim Jin-soo, former Commissioner of the Korea Food and Drug Administration and a standing advisor to AdipoLABs, gave a lecture on the overall understanding of the Korean medical and health industry, followed by the clinical treatment effects and principles of the high-frequency hyperthermia cancer treatment device 'REMISSION 1℃', which has been stealing the limelight at home and abroad recently. CEO Han Sung-ho's lecture strengthened overall understanding and cooperation between Chengdu, China and the medical and health industry in Korea.

In particular, Dr. Kim Eui-shin, a tenured professor at the University of Texas MD Anderson Cancer Center, participated, further enhancing the conference's authority.

At the center of the exchange conference with China, AdipoLABs Co., Ltd., the corporate representative of IVRA, has been steadily exporting and donating high-frequency hyperthermia cancer treatment device REMISSION 1℃ for the purpose of cancer treatment and clinical trials in order to advance into China. This is the result of influencing high-ranking city officials and the related medical community.

In addition, it was the beginning of cooperation to strengthen exchanges between domestic hospitals and medical companies for the medical device exhibition to be held in Chengdu in 2024 as well as related academic seminars.

▲ Officials from medical companies in Chengdu, China visited the Catholic University of Korea's Seoul St. Mary's Hospital (left) and Suwon Amirang Clinic to experience advanced cancer treatment using the high-frequency hyperthermia cancer treatment device REMISSION 1℃.

Prior to the conference, Chinese officials toured the Catholic University of Korea's Seoul St. Mary's Hospital and Suwon Amirang Clinic to experience advanced cancer treatment sites and acquire a lucid understanding of hyperthermia immunotherapy.

Meanwhile, Han Sung-ho, CEO of AdipoLABs Co., Ltd., which has developed and distributed REMISSION 1℃, said, “REMISSION 1℃ is a cancer treatment device that is already being used for cancer patients at Boaohengda International Hospital in Hainan Province, China.” He said, “I hope that through this conference, high-frequency hyperthermia cancer treatment devices will be exported to Chengdu, China and utilized for more cancer patients.”

In particular, he emphasized, “By expanding the Chinese medical device market, we have secured a bridgehead for further growth in 2024.”

link: 아디포랩스, 중국 시장 진출 교두보 마련:후생신보 (whosaeng.com)